Literature DB >> 20010065

Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer.

Arda Kayhan1, Xiaobing Fan, Aytekin Oto.   

Abstract

Prostate cancer remains a major health concern for the male population. During the past decade, a dramatic increase in prostate-specific antigen and transurethral resection of the prostate has resulted in increased detection rate of small lesions and increased incidence of this disease. Needle biopsies in asymptomatic men have also contributed to the increased incidence of prostate cancer, leading to an increasing incidence-to-mortality ratio. Magnetic resonance imaging (MRI) is the modality of choice in prostate cancer patients with increased prostate-specific antigen levels before or after prostate cancer diagnosis confirmed by biopsy and T2-weighted imaging (T2W) has been used as a standard technique in detection. During the last decade, dynamic contrast-enhanced MRI has emerged as one of the main techniques used in multiparametric MRI of the prostate gland in cancer patients. Dynamic contrast-enhanced MRI has been routinely used for detection and diagnosis of the tumor, for staging and monitoring the therapeutic response, as well as for guiding targeted biopsies in patients with suspected prostate cancer or with a negative biopsy result. In this article, we are going to review the analysis techniques of dynamic contrast-enhanced MRI and its various clinical applications in prostate cancer patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20010065     DOI: 10.1097/RMR.0b013e3181c0e2fa

Source DB:  PubMed          Journal:  Top Magn Reson Imaging        ISSN: 0899-3459


  2 in total

1.  Comparison of pelvic phased-array versus endorectal coil magnetic resonance imaging at 3 Tesla for local staging of prostate cancer.

Authors:  Bum Soo Kim; Tae-Hwan Kim; Tae Gyun Kwon; Eun Sang Yoo
Journal:  Yonsei Med J       Date:  2012-05       Impact factor: 2.759

2.  The value of prostate MRI with endorectal coil in detecting seminal vesicle involvement in patients with prostate cancer.

Authors:  Mahyar Ghafoori; Manijeh Alavi; Madjid Shakiba; Kamal Hoseini
Journal:  Iran J Radiol       Date:  2015-01-17       Impact factor: 0.212

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.